Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q2 2025 value amounting to $88000.0.

  • Ironwood Pharmaceuticals' Cash from Financing Activities rose 10017.82% to $88000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was -$14.8 million, marking a year-over-year increase of 8965.43%. This contributed to the annual value of -$107.0 million for FY2024, which is 13859.5% down from last year.
  • As of Q2 2025, Ironwood Pharmaceuticals' Cash from Financing Activities stood at $88000.0, which was up 10017.82% from $6000.0 recorded in Q1 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Cash from Financing Activities peaked at $399.1 million during Q2 2023, and registered a low of -$150.3 million during Q2 2022.
  • Its 5-year average for Cash from Financing Activities is -$4.0 million, with a median of -$7.4 million in 2024.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Cash from Financing Activities skyrocketed by 82000.0% in 2021 and then crashed by 950878.29% in 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$18.6 million in 2021, then surged by 115.1% to $2.8 million in 2022, then tumbled by 1914.11% to -$50.9 million in 2023, then skyrocketed by 70.75% to -$14.9 million in 2024, then skyrocketed by 100.59% to $88000.0 in 2025.
  • Its last three reported values are $88000.0 in Q2 2025, $6000.0 for Q1 2025, and -$14.9 million during Q4 2024.